CN102861054B - Houttuynoid D在制备抑制肝脏成纤维细胞增殖药物中的应用 - Google Patents
Houttuynoid D在制备抑制肝脏成纤维细胞增殖药物中的应用 Download PDFInfo
- Publication number
- CN102861054B CN102861054B CN201210418104.5A CN201210418104A CN102861054B CN 102861054 B CN102861054 B CN 102861054B CN 201210418104 A CN201210418104 A CN 201210418104A CN 102861054 B CN102861054 B CN 102861054B
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- medicine
- hepatic fibrosis
- cell
- proliferation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ROCYDQPSKYPRJK-KXDBBDCJSA-N 2-[3,4-dihydroxy-2-(2-oxoundecyl)phenyl]-5,7-dihydroxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound CCCCCCCCCC(=O)CC1=C(O)C(O)=CC=C1C1=C(O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 ROCYDQPSKYPRJK-KXDBBDCJSA-N 0.000 title claims abstract description 38
- 239000003814 drug Substances 0.000 title claims abstract description 30
- 210000002950 fibroblast Anatomy 0.000 title claims abstract description 23
- 230000035755 proliferation Effects 0.000 title claims abstract description 18
- 210000004185 liver Anatomy 0.000 title claims abstract description 14
- 230000002401 inhibitory effect Effects 0.000 title abstract description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims description 11
- 206010019668 Hepatic fibrosis Diseases 0.000 abstract description 16
- 238000012360 testing method Methods 0.000 abstract description 6
- 230000000144 pharmacologic effect Effects 0.000 abstract description 5
- 208000019425 cirrhosis of liver Diseases 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 3
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 14
- 230000004663 cell proliferation Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 7
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 7
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000004024 hepatic stellate cell Anatomy 0.000 description 5
- 208000009889 Herpes Simplex Diseases 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 230000003602 anti-herpes Effects 0.000 description 4
- 240000000691 Houttuynia cordata Species 0.000 description 3
- 235000013719 Houttuynia cordata Nutrition 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 229930190556 houttuynoid Natural products 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000012 chronic liver injury Toxicity 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000004500 stellate cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210418104.5A CN102861054B (zh) | 2012-10-27 | 2012-10-27 | Houttuynoid D在制备抑制肝脏成纤维细胞增殖药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210418104.5A CN102861054B (zh) | 2012-10-27 | 2012-10-27 | Houttuynoid D在制备抑制肝脏成纤维细胞增殖药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102861054A CN102861054A (zh) | 2013-01-09 |
CN102861054B true CN102861054B (zh) | 2013-07-10 |
Family
ID=47440372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210418104.5A Active CN102861054B (zh) | 2012-10-27 | 2012-10-27 | Houttuynoid D在制备抑制肝脏成纤维细胞增殖药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102861054B (zh) |
-
2012
- 2012-10-27 CN CN201210418104.5A patent/CN102861054B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN102861054A (zh) | 2013-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104095859A (zh) | 闭花木酮Cleistanone的O-(哌啶基)乙基衍生物在制备抗肝纤维化药物中的应用 | |
CN102861054B (zh) | Houttuynoid D在制备抑制肝脏成纤维细胞增殖药物中的应用 | |
CN103251614A (zh) | Aspeverin在制备抑制肝脏成纤维细胞增殖药物中的应用 | |
CN103446131A (zh) | Lycojaponicumin B在抑制肝脏成纤维细胞增殖药物中的应用 | |
CN103446132A (zh) | Lycojaponicumin A在抑制肝脏成纤维细胞增殖药物中的应用 | |
CN102872114A (zh) | Houttuynoid E在抑制肝脏成纤维细胞增殖药物中的应用 | |
CN102885808A (zh) | Aphanamixoid A在抑制肝脏成纤维细胞增殖药物中的应用 | |
CN102872009A (zh) | Eryngiolide A在抑制肝脏成纤维细胞增殖药物中的应用 | |
CN103356533A (zh) | Sarcaboside A在抑制肝脏成纤维细胞增殖药物中的应用 | |
CN102218047B (zh) | 治疗耐药菌感染的药物及其活性成分在制药中的应用 | |
CN103356523A (zh) | Sarcaboside B在抑制肝脏成纤维细胞增殖药物中的应用 | |
CN102872107A (zh) | Houttuynoid A在抑制肝脏成纤维细胞增殖药物中的应用 | |
CN103315990A (zh) | Nardoaristolones A在制备抑制肝脏成纤维细胞增殖药物中的应用 | |
CN103393697A (zh) | Chukrasone A在抑制肝脏成纤维细胞增殖药物中的应用 | |
CN102872136A (zh) | Houttuynoid B在抑制肝脏成纤维细胞增殖药物中的应用 | |
CN102872079A (zh) | Houttuynoid C在抑制肝脏成纤维细胞增殖药物中的应用 | |
CN103463074A (zh) | Lycojaponicumin C在抑制肝脏成纤维细胞增殖药物中的应用 | |
CN103463011B (zh) | Fluevirosines A在制备抑制肝脏成纤维细胞增殖药物中的应用 | |
CN106420706A (zh) | Linderolide H 在制备抑制肝脏成纤维细胞增殖药物中的应用 | |
CN103446090A (zh) | Incarviatone A在抑制肝脏成纤维细胞增殖药物中的应用 | |
CN103372005A (zh) | Chukrasone B在抑制肝脏成纤维细胞增殖药物中的应用 | |
CN103536600A (zh) | Phyllanthoid A在制备抑制肝脏成纤维细胞增殖药物中的应用 | |
CN103479647A (zh) | Kadcoccitones A在制备抑制肝脏成纤维细胞增殖药物中的应用 | |
CN103127149A (zh) | Gypensapogenin B在抑制肝脏成纤维细胞增殖药物中的应用 | |
CN102895240A (zh) | Gypensapogenin A在抑制肝脏成纤维细胞增殖药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: RUDONG TECHNOLOGY CENTER Free format text: FORMER OWNER: NANJING UNIVERSITY Effective date: 20141225 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210093 NANJING, JIANGSU PROVINCE TO: 226400 NANTONG, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20141225 Address after: 226400 No. 66 Youyi West Road, dug Town, Rudong County, Jiangsu, Nantong Patentee after: Rudong science and Technology Center Address before: 210093 Nanjing, Gulou District, Jiangsu, No. 22 Hankou Road Patentee before: Nanjing University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200420 Address after: No. 10, Fandi South Road, juegang Town, Rudong County, Nantong City, Jiangsu Province Patentee after: Rudong industrial and commercial information consulting service center Address before: 226400 No. 66 Youyi West Road, dug Town, Rudong County, Jiangsu, Nantong Patentee before: Rudong science and Technology Center |
|
TR01 | Transfer of patent right |
Effective date of registration: 20211220 Address after: Fengli town Xinjian West Road, Rudong County, Nantong City, Jiangsu Province 226400 Patentee after: Rudong Wenyuan investment and Development Co., Ltd Address before: 226400 No.10 Fandi South Road, juegang Town, Rudong County, Nantong City, Jiangsu Province Patentee before: Rudong industrial and commercial information consulting service center |
|
TR01 | Transfer of patent right |